Biogen CEO Plots A Slow Return To Growth As Revenue Set To Shrink Again In 2023

Cost Cuts, R&D Prioritization, Deals All On The Table

 
• By Mandy Jackson
  
Q4 on red background, fourth quarter cover or poster
Biogen reported a 7% revenue decline for Q4 and the full year of 2022 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip